Navigation Links
Celladon Corporation Announces Publication of Long Term Follow-Up Results from the MYDICAR CUPID 1 Trial in Advanced Heart Failure
Date:9/26/2013

SAN DIEGO, Sept. 26, 2013 /PRNewswire/ -- Celladon Corporation, a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, today announced the full three year long-term follow up results from Phase 2a of the CUPID 1 trial in the online publication of Circulation Research. Phase 2a of the CUPID 1 trial investigated Celladon's product candidate MYDICAR in three dose groups for the treatment of advanced heart failure.

"The long term trends observed in the full three years of follow up from the CUPID 1 trial in the MYDICAR high dose group are very encouraging," said Krisztina Zsebo, Ph.D., President and Chief Executive Officer of Celladon Corporation. "The duration of clinical response in the high dose group, coupled with the favorable trend in mortality and lack of safety concerns, leaves us optimistic for future development of MYDICAR."

In the additional two year follow up period of the CUPID 1 trial, the durability of reduced cardiovascular and terminal events previously observed in the MYDICAR high dose cohort at 12 months was maintained. The following recurrent cardiovascular and terminal events were tracked over the three years in all MYDICAR dose groups: myocardial infarction, worsening heart failure, heart failure-related hospitalization, left ventricular assist device (LVAD) placement, heart transplantation, and all-cause death. The risk of pre-specified recurrent cardiovascular events through full three years of follow up was reduced by 82% in the high dose group compared to the placebo group (p=0.048, where p-value is the statistical probability of a result due to chance alone).

In addition, the survival probability over time was higher for patients in all MYDICAR dose groups compared to the placebo group, especially in the high dose group. At three years post-administration, there we
'/>"/>

SOURCE Celladon Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Celladon Corporation Named a 2012 Fierce 15 Company by FierceBiotech
2. Celladon Corporation To Present at BioCentury Future Leaders in the Biotech Industry Conference
3. Celladon Corporation and SIRO Clinpharm Announce Presentation at "Statisticians in the Pharmaceutical Industry International Conference"
4. Celladon Corporation Selected as Winner of Red Herrings "Top 100 North America Tech Startup"
5. Celladon Corporation Announces Pre-clinical Study Demonstrating Inhalable MYDICAR Reverses Pulmonary Arterial Hypertension (PAH)
6. Celladon Corporation Announces Appointment of Gregg Alton and Graham Cooper to its Board of Directors
7. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2012 Financial Results
8. Kensey Nash Corporation Announces Achievement of $6 Million Milestone From Spectranetics Corporation
9. China Cord Blood Corporation Announces Results of 2011 Annual General Meeting
10. Neogen Corporation Announces 2nd Quarter Results Conference Call
11. Luminex Corporation to Present at JP Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... SoundConnect , an award winning ... to announce the addition of Adobe Connects Learning ... tools to quickly deploy and manage online courses ... for desktop and mobile learning solutions. , Adobe ... online training solution, enabling organizations to deploy, measure, ...
(Date:7/30/2014)... 30, 2014 Regulus Therapeutics Inc . ... the discovery and development of innovative medicines targeting microRNAs, ... highlights for the quarter ended June 30, 2014 on ... close. Regulus will host a conference ... 5:00 pm Eastern Daylight Time to discuss its second ...
(Date:7/30/2014)... 30, 2014 A study presented at ... and efficacy of CSL Behring,s C1 Inhibitor (C1-INH) ... in highly sensitized patients. C1-INH is a human ... system. The study shows that post-transplant ... the levels of complement components 3 and 4, ...
(Date:7/30/2014)... Selexis SA , a serial ... and mammalian cell line development, announced today new data ... be presented at the 10th Annual Cell Line ... – 10, 2014 at the Double Tree by Hilton ... abstract will be presented during an oral presentation: , ...
Breaking Biology Technology:SoundConnect Enhances Portfolio with Adobe Connect Learning Management System (LMS) 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 3Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 2Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 3Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 2Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 3
... Medco Health,Solutions, Inc. (NYSE: MHS ) Chairman ... members of his senior management team, will present an,overview ... and institutional investors during its annual Analyst Day,conference on ... of Pharmacy," is scheduled to begin at 8 a.m. ...
... Abercrombie, Pfizer R&D Head Martin,Mackay, HHS Deputy Secretary Tevi ... Agenda at FDA/CMS Summit 2007, WASHINGTON, Nov. 15 ... drug approvals. Unfortunately for the biopharma sector and,investors, it,s ... on track,to grant marketing approval to 18 or fewer ...
... Brad Thompson, President,and CEO of Oncolytics Biotech Inc. ... of the company at Toronto CFA Society on ... at the National Club, 303 Bay,Street, Toronto at ... Oncolytics is a Calgary-based biotechnology company focused on ...
Cached Biology Technology:Medco to Webcast Annual Analyst Day Conference 2So Long, Old Friend: The End of the Blockbuster Drug Era? What 2008 Holds for Bringing Drugs to Market 2So Long, Old Friend: The End of the Blockbuster Drug Era? What 2008 Holds for Bringing Drugs to Market 3Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society 2
(Date:7/30/2014)... a massive collection of 20-million-year-old amber found in the ... effort is yielding fresh insights into ancient tropical insects ... is fully curated, a task that will take many ... collection in the world, the researchers report. , ... of a pygmy locust, a tiny grasshopper the size ...
(Date:7/30/2014)... of Engineering recently received a $330,000 award from ... synthesis of organic nanorods." , According to ... and utilization of functional materials, devices, and systems ... in scaling up nanotechnology is the lack of ... one device. A research team led by Dr. ...
(Date:7/30/2014)... Wallerian degeneration is a subject of major interest ... differentially regulated during the distinct stages of Wallerian ... differentiation and dedifferentiation. Although gene expression responses in ... peripheral nerve injury are known, differences in gene ... unclear. Dr. Dengbing Yao and co-workers from Nantong ...
Breaking Biology News(10 mins):Decades-old amber collection offers new views of a lost world 2NSF grant to Wayne State supports new concept for manufacturing nanoscale devices 2
... ON (September 05, 2011) You may think your lack ... because you,re lazy, but McMaster University researchers have discovered it ... made their unexpected finding while working with healthy, specially-bred mice, ... exercise removed. The genes control the protein AMP-activated protein kinase ...
... It is now widely accepted that the species Homo ... world. But did those early humans interbreed with more ... erectus, the "upright walking man," Homo habilis, the ... cave-painting fame? Direct studies of ancient DNA from ...
... Ten variants of the deadly Escherichia coli ... sequenced across the world. The unprecedented level of collaboration ... the outbreak arose, says a scientist at the Society ... the bacterium started in early June at BGI, China. ...
Cached Biology News:McMaster researchers find missing genes may separate coach potato from active cousin 2Ancient humans were mixing it up 2Ancient humans were mixing it up 3Ancient humans were mixing it up 4Crowd-sourcing the E. coli O104:H4 outbreak 2
Phosphotyrosine IgG mouse monoclonal antibody: Alkaline Phosphatase conjugate...
Rabbit polyclonal to GPCR G2A ( Abpromise for all tested applications). entrezGeneID: 29933 SwissProtID: Q9UNW8...
... This reagent has been developed ... for the reduction of nonspecific background ... Traditional methods describe blocking peroxidase with ... hydrogen peroxide in combination with additional ...
Rabbit polyclonal to Wilms Tumor Protein ( Abpromise for all tested applications). entrezGeneID: 7490 SwissProtID: P19544...
Biology Products: